复发肿瘤与治疗所致效应在高级别胶质瘤强化和非强化病灶中具有不同MR特征
本前瞻性研究分析139例疑似复发高等级胶质瘤患者的291份组织样本,在对比增强病灶中rCBV升高与复发肿瘤病理相关(P<0.03),在非增强病灶中nCho和CNI升高与复发肿瘤病理相关(P<0.008),CNI均值切点2.7在非增强病灶中区分治疗效应与复发肿瘤的平均灵敏度和特异度分别为0.61和0.81。
要点
- 对比增强病灶中rCBV升高与复发肿瘤病理相关(P<0.03)。
- 非增强病灶中nCho和CNI升高与复发肿瘤病理相关(P<0.008)。
- 非增强病灶中CNI均值切点2.7区分治疗效应与复发肿瘤的平均灵敏度和特异度分别为0.61和0.81。
核心结论
- 结果支持rCBV有助于在对比增强病灶中区分治疗效应与复发肿瘤,代谢参数可能更适于区分非增强病灶中的复发肿瘤与治疗相关改变。
研究设计与样本
- 前瞻性研究分析139例因疑似复发接受术前3T MRI和手术患者的291份组织样本(222份复发肿瘤、69份治疗效应),样本在影像上有已知坐标。
- 在每份组织样本位置检验灌注加权、弥散加权和MR波谱成像的8个MR参数值与组织病理学结果的关联,对比增强病灶和非增强病灶组织样本分别采用广义估计方程模型。
- 采用受试者工作特征曲线分析和5折交叉验证评估个体切点值。
主要发现
- 对比增强病灶组织样本中,相对脑血容量(rCBV)升高与复发肿瘤病理存在相关(P < 0.03)。
- 非增强病灶组织样本中,标准化胆碱(nCho)和胆碱与NAA指数(CNI)升高与复发肿瘤病理存在相关(P < 0.008)。
- CNI均值切点2.7表现最佳,在非增强病灶中区分治疗效应与复发肿瘤的平均灵敏度和特异度分别为0.61和0.81。
关键数值与推荐
- 对比增强病灶中rCBV升高与复发肿瘤病理相关(P < 0.03)。
- 非增强病灶中nCho和CNI升高与复发肿瘤病理相关(P < 0.008)。
- 非增强病灶中CNI均值切点2.7区分治疗效应与复发肿瘤的平均灵敏度和特异度分别为0.61和0.81。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Differentiating treatment-induced injury from recurrent high-grade glioma is an ongoing challenge in neuro-oncology, in part due to lesion heterogeneity. This study aimed to determine whether different MR features were relevant for distinguishing recurrent tumor from the effects of treatment in contrast-enhancing lesions (CEL) and non-enhancing lesions (NEL). METHODS: This prospective study analyzed 291 tissue samples (222 recurrent tumor, 69 treatment-effect) with known coordinates on imaging from 139 patients who underwent preoperative 3T MRI and surgery for a suspected recurrence. 8 MR parameter values were tested from perfusion-weighted, diffusion-weighted, and MR spectroscopic imaging at each tissue sample location for association with histopathological outcome using generalized estimating equation models for CEL and NEL tissue samples. Individual cutoff values were evaluated using receiver operating characteristic curve analysis with 5-fold cross-validation. RESULTS: In tissue samples obtained from CEL, elevated relative cerebral blood volume (rCBV) was associated with the presence of recurrent tumor pathology (P < 0.03), while increases in normalized choline (nCho) and choline-to-NAA index (CNI) were associated with the presence of recurrent tumor pathology in NEL tissue samples (P < 0.008). A mean CNI cutoff value of 2.7 had the highest performance, resulting in mean sensitivity and specificity of 0.61 and 0.81 for distinguishing treatment-effect from recurrent tumor within the NEL. CONCLUSION: Although our results support prior work that underscores the utility of rCBV in distinguishing the effects of treatment from recurrent tumor within the contrast enhancing lesion, we found that metabolic parameters may be better at differentiating recurrent tumor from treatment-related changes in the NEL of high-grade gliomas.
引用
- Cluceru J, Nelson SJ, Wen Q, et al. Recurrent tumor and treatment-induced effects have different MR signatures in contrast enhancing and non-enhancing lesions of high-grade gliomas. Neuro Oncol. 2020. PMID: 32319527. doi:10.1093/neuonc/noaa094
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。